Member Press Release from: Avery Dennison

Avery Dennison Smartrac introduces ultra-small Minidose U8 RAIN RFID inlays for pharma applications

Smallest RFID product on the market to pass ARC certification (Spec S), and to be approved for use by DoseID consortium.
 

GLENDALE, Calif. – April 6, 2021 — Avery Dennison (NYSE: AVY) today launched its ultra-small Minidose U8 RAIN RFID inlays for pharma applications, the first products on the market to receive ARC certification (Spec S) from Auburn University’s RFID Lab, and to be approved for use by DoseID. Minidose U8 inlays have been carefully designed to blend performance, cost-effectiveness and size to work on multiple items such as syringes, plastic and glass vials, as well as packaging designs used for all kinds of pharmaceuticals.

Minidose U8 is a UHF RFID product performing in the standard UHF RFID frequency band between 860MHz-960MHz. It has a small form factor of 22x12mm, is available in dry and wet formats, and uses NXP’s proven UCODE®️ 8 IC. 

Hal Hikita, head of product line management at Avery Dennison Smartrac, said, “As the smallest product currently on the market that has passed ARC Spec S, Minidose U8 meets the needs of a wide range of pharmaceutical item-level packaging solutions. The inlay is qualified to perform robustly on clear and amber glass as well as plastics and syringes even when filled with pharmaceuticals and biologicals, thereby unlocking critical RFID value for healthcare, pharmacies, and laboratory asset management.”

Avery Dennison Smartrac is the key RFID partner for Kit Check, a leading provider of automated medication tracking and diversion detection solutions for hospital pharmacies in the U.S. The Kit Check RFID-enabled inventory management solution helps hospitals modernize restocking processes, and automate them to save redundant drug spend and ensure patient safety.

According to Kevin MacDonald, CEO and co-founder of Kit Check, “Since our inception, Kit Check has experienced great success working with Avery Dennison Smartrac to design and implement RFID tag designs. We tag a myriad of pharmaceuticals through the Kit Check solution to deliver the right medicine to the right patient at the right time, every time.” 

Avery Dennison Smartrac is a leading RFID innovator in the healthcare and pharmaceutical market, and designs solutions to meet specific customer requirements with the goal of ensuring patient safety, increasing nursing “time to care,” and decreasing inefficiencies in the operational process. In addition to designing RFID products that enable item-level tagging in the pharmaceutical sector, the company produces a wide range of other products for many industry sectors. 

Available as wet and dry inlays with the NXP UCODE 8 IC, Minidose U8 will ship in volume from Q2 2021. Minidose U8 inlays are compliant with ISO 9001:2015 Quality Management and ISO 14001:2015 Environmental Management, which ensure a reliable and state-of-the-art product that meets a variety of application needs. They are manufactured according to the industry’s highest quality standards, as confirmed by the RFID Lab at Auburn University, which awarded Avery Dennison Smartrac its first-ever ARC accreditation for overall design and manufacturing quality.

Media contact
Christian Achenbach
Communications Manager, Avery Dennison Smartrac
christian.achenbach@eu.averydennison.com

DOWNLOAD IMAGE


About Avery Dennison
Avery Dennison (NYSE: AVY) is a global materials science company specializing in the design and manufacture of a wide variety of labeling and functional materials. The company’s products, which are used in nearly every major industry, include pressure-sensitive materials for labels and graphic applications; tapes and other bonding solutions for industrial, medical, and retail applications; tags, labels and embellishments for apparel; and radio frequency identification (RFID) solutions serving retail apparel and other markets. Headquartered in Glendale, California, the company employs more than 32,000 employees in more than 50 countries. Reported sales in 2020 were $7.0 billion. Learn more at www.averydennison.com.

About Kit Check
Kit Check® is the leading provider of automated solutions for hospital pharmacies in the U.S., bringing visibility, simplicity, and predictability to the complex world of medication supply management. Our groundbreaking Medication Intelligence™ solutions provide item-level visibility, workflow simplicity, and actionable analytics, empowering stakeholders to deliver the right medicine to the right patient at the right time, every time. To date, our more than 700 U.S. and Canadian hospital partners have adopted Kit Check solutions to solve the most challenging of healthcare problems. Kit Check Solutions help providers save time managing inventory, prevent diversion at their facilities, save money on medication spend, and ensure patient safety. More information about Kit Check and our software solutions can be found at kitcheck.com.

About DoseID
DoseID is the first member driven industry consortium for the use of radio-frequency identification (RFID) technology in the healthcare space. DoseID consists of industry innovators who are committed to increasing the interoperability, quality and performance of RFID-tagged products as they move through the pharmaceutical supply chain from manufacturer to patient. 

The DoseID RFID tag certification is provided by Auburn University RFID Lab’s ARC Program. This ensures that parties not only meet the standards set by the consortium, but that the established standards meet the needs of industry players including pharmaceutical manufacturers, 503b compounding pharmacies, pharmacy automation vendors, and inlay and tag manufacturers. Members of DoseID, which launched in August 2020, hail from other companies across the pharmaceutical supply chain including health systems. Learn more about DoseID at doseid.com